Application of jatrorrhizine hydrochloride to reversion of drug tolerance of pancreatic cancer cells

Abstract

The invention relates to the technical field of biomedicine, in particular to an application of jatrorrhizine hydrochloride to reversion of drug tolerance of pancreatic cancer cells. Under the synergistic reaction of the jatrorrhizine hydrochloride, gemcitabine has notable restraining effects on the pancreatic cancer cells, and can reverse the drug tolerance of pancreatic cancer drug tolerance cells to the gemcitabine. Through research of pancreatic cancer Panc-1 cells and gemcitabine drug tolerance Panc-1 cells, the inventor finds that under the action of jatrorrhizine hydrochloride, the drugsensitivity of the pancreatic cancer cells to the gemcitabine is strengthened, low concentration gemcitabine and the jatrorrhizine hydrochloride are combined for use, so that the effect of high-concentration gemcitabine on drug tolerance Panc-1 cells can be achieved, and along with increment of the concentration of the jatrorrhizine hydrochloride, when the jatrorrhizine hydrochloride and the gemcitabine are combined for use, growth of the drug tolerance Panc-1 cells can be effectively restrained. The growth restraining effect of combination for use is far higher than single use of the gemcitabine, and the drug tolerance of the drug tolerance Panc-1 cells on the gemcitabine is notably reversed.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of jatrorrhizine hydrochloride in reversing drug resistance of pancreatic cancer cells to gemcitabine. Background technique [0002] Pancreatic cancer is currently one of the most malignant and refractory gastrointestinal tumors, and its incidence is on the rise worldwide. Because there are usually no symptoms in the early stage, and these symptoms are usually non-specific, therefore, when patients are found, they often Has entered the advanced stage, the mortality rate is almost 100%, and the 5-year survival rate is less than 5%. The early diagnosis rate of pancreatic cancer is not high. The morbidity and mortality of pancreatic cancer rank 12th and 7th among malignant tumors in the world, respectively. According to data from the National Cancer Center, the number of pancreatic cancer cases in my country accounts for about 2.42% of the number of malignant t...

AI Technical Summary

Problems solved by technology

At present, the efficacy of gemcitabine-based first-line chemotherapy for advanced pancreatic cancer has stagnated at the plateau stage, and due to the special biological characteristics of pancreatic cancer cells, it is not very sensitive to other chemotherapy except gemcitabine. Therefore, gemcitabine is the first choice for the treatment of pancreatic cancer. The drug of choice, but in the clinical practice of pancreatic cancer, many patients have congenital or acquired chemotherapy resistance to gemcitabine, which limits the clinical application of gemcitabine and increases the difficulty of treatment

Images